About Us

Kalohexis is a clinical-stage biopharmaceutical company shaping the next era of metabolic disease care.

At Kalohexis, we are unlocking the therapeutic potential of the central melanocortin system for diseases characterized by dysregulation of appetite, body composition, and energy balance. The melanocortin system is the body’s natural regulator of metabolic homeostasis but has been misunderstood and suboptimally targeted in the past. With deep expertise in melanocortin biology, our team developed a proprietary pipeline of therapeutic peptide candidates designed to safely and effectively modulate melanocortin-3 and -4 receptors (MC3R/MC4R) to treat metabolic disorders, such as obesity and cancer cachexia, and help people live healthier lives.

Leadership

Russell Potterfield, MBA, Chief Executive Officer of Kalohexis.
Russell Potterfield, M.B.A.

CHIEF EXECUTIVE OFFICER

Smiling bald man with glasses and goatee
Daniel Marks, M.D., Ph.D.

Chief Scientific Officer

Tony Mitchell, Chief Financial Officer of Kalohexis.
Tony Mitchell, M.B.A.

CHIEF FINANCIAL OFFICER

Barry Badeau, PhD, Chief Development Officer of Kalohexis.
Barry Badeau, Ph.D.

Chief Development Officer

Jordan Delev, Chief Discovery Officer of Kalohexis.
Jordan Delev

Chief Discovery Officer

Board of Directors


Russell Potterfield, M.B.A.

CHAIRMAN


Daniel Marks, M.D., Ph.D.

DIRECTOR


Eugene (Gene) Gerke

Director


Bobby Sandage, Ph.D.

Director


Jeffrey Sherman, M.D., FACP

Director


Garry Menzel, Ph.D., M.B.A.

Director


Thomas Forest Farb-Horch

DIRECTOR

Scientific Advisors


Andrew Butler, Ph.D.

Advisor


Michael Cowley, Ph.D.

Advisor


Richard Skipworth, M.D.

Advisor